Wang Hua, Chen Qingyong, Li Yingying, Jing Xianchao, Yang Jiefu
Beijing Hospital, Peking University West China Hospital, Sichuan University.
Cardiol J. 2018;25(2):245-253. doi: 10.5603/CJ.a2017.0068. Epub 2017 Jun 14.
Growth differentiation factor-15 (GDF-15), a biomarker associated with remodeling, oxidative stress and inflammation, has been used to stratify heart failure (HF) patients. However, its prognostic value in Chinese HF patients is still unknown.
GDF-15 levels were examined on admission in 272 consecutive HF patients in Beijing Hospital (a Chinese tertiary medical center) by a commercial enzyme-linked immunosorbent assay. We recorded the incidence of all-cause mortality and/or readmission for HF during a median follow-up period of 558 days. Patients were stratified according to the tertiles of GDF-15.
Fifty-three (19.5%) patients died and 103 (37.9%) patients had major adverse cardiac events (MACE) which included the composite outcome of all-cause mortality or readmission for HF at the end of follow-up. Kaplan-Meier survival curves showed that the third tertile of GDF-15 was associated with increased rate of all-cause mortality (compared with the first and second tertiles, log rank p = 0.001 and 0.001, respectively) or MACE (compared with the first and second tertiles, log rank p = 0.002 and p < 0.001, respectively). In addition, multivariate Cox regression model showed that the highest tertile of GDF-15 was independently associated with increased risk of all-cause death (hazard ratio = 5.95, 95% confidence interval 1.88-18.78, p = 0.002) compared with the lowest tertile after adjustment for related clinical variables such as age, renal function or N-terminal pro-B-type natriuretic peptide.
Plasma GDF-15 is an independent predictor of all-cause mortality in Chinese patients with HF. It may potentially be used to stratify and prognosticate HF patients.
生长分化因子15(GDF-15)是一种与重塑、氧化应激和炎症相关的生物标志物,已被用于对心力衰竭(HF)患者进行分层。然而,其在中国HF患者中的预后价值仍不清楚。
采用商业酶联免疫吸附测定法,对北京医院(一家中国三级医疗中心)连续收治的272例HF患者入院时的GDF-15水平进行检测。我们记录了在中位随访期558天内全因死亡率和/或HF再入院率。根据GDF-15的三分位数对患者进行分层。
53例(19.5%)患者死亡,103例(37.9%)患者发生主要不良心脏事件(MACE),MACE包括随访结束时全因死亡率或HF再入院的复合结局。Kaplan-Meier生存曲线显示,GDF-15的第三个三分位数与全因死亡率增加相关(与第一个和第二个三分位数相比,对数秩检验p分别为0.001和0.001)或MACE增加相关(与第一个和第二个三分位数相比,对数秩检验p分别为0.002和p<0.001)。此外,多变量Cox回归模型显示,在对年龄、肾功能或N末端B型利钠肽原等相关临床变量进行调整后,与最低三分位数相比,GDF-15的最高三分位数与全因死亡风险增加独立相关(风险比=5.95,95%置信区间1.88-18.78,p=0.002)。
血浆GDF-15是中国HF患者全因死亡率的独立预测因子。它可能潜在地用于对HF患者进行分层和预后评估。